The Patent Finder

Eolas Therapeutics, Inc.

Also on record
Records under this name other than patents Eolas Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 7 of 7 · Back to Eolas Therapeutics, Inc.

PatentTitleStatus Expires Confidence
US 9,440,982Substituted prolines/piperidines as orexin receptor antagonists
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,499,517Substituted prolines / piperidines as orexin receptor antagonists
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,221,170Difluoropyrrolidines as Orexin Receptor Modulators
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,894,789Halo-Substituted Piperidines as Orexin Receptor Modulators
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,434,236Halo-Substituted Piperidines as Orexin Receptor Modulators
Formerly held
In force
 · High confidence
In forceHigh confidence
US 12,084,437Halo-Substituted Piperidines as Orexin Receptor Modulators
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 9,896,452Substituted prolines/piperidines as orexin receptor antagonists
Formerly held
Lapsed on the fee record
Ended Feb 20, 2026 · From the USPTO record
Lapsed on the fee recordEnded Feb 20, 2026From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited